| Recruiting | An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomer NCT06664814 | National Human Genome Research Institute (NHGRI) | Phase 2 |
| Recruiting | A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental G NCT07220083 | Boehringer Ingelheim | Phase 3 |
| Recruiting | A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS) NCT07268638 | Akebia Therapeutics | Phase 2 |
| Recruiting | Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis NCT07219121 | Travere Therapeutics, Inc. | Phase 4 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 1 NCT06500702 | Sanofi | Phase 2 |
| Not Yet Recruiting | Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1 NCT06443034 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | AMPK-activation by Metformin in FSGS: AMP-FSGS NCT06090227 | Yale University | Phase 1 / Phase 2 |
| Recruiting | A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects NCT05942625 | Hansoh BioMedical R&D Company | Phase 1 |
| Recruiting | taVNS for FRNS in Children NCT05588063 | Northwell Health | N/A |
| Recruiting | ARREST-NEPHROSIS - Austrian Resistant Nephrotic Syndrome Treatment Response Registry and Biobank NCT06162546 | Christoph Aufricht | — |
| Recruiting | Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Diseas NCT05650619 | University of Michigan | — |
| Recruiting | A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) NCT05583942 | Northwell Health | N/A |
| Completed | Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis NCT05267262 | River 3 Renal Corp. | Phase 2 |
| Terminated | Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclero NCT05441826 | Tenet Medicines | Phase 2 |
| Recruiting | NEPTUNE Match Study NCT04571658 | University of Michigan | N/A |
| Completed | Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy) NCT05200871 | Travere Therapeutics, Inc. | — |
| Recruiting | Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases NCT05003986 | Travere Therapeutics, Inc. | Phase 2 |
| Active Not Recruiting | Atrasentan in Patients With Proteinuric Glomerular Diseases NCT04573920 | Novartis Pharmaceuticals | Phase 2 |
| Recruiting | Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA- NCT04065438 | Kaneka Medical America LLC | N/A |
| Completed | Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change NCT04009668 | University of Michigan | Phase 2 |
| Completed | Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease NCT04369183 | Istanbul University | — |
| Completed | PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant NCT03763643 | University of Minnesota | EARLY_Phase 1 |
| Recruiting | KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis NCT03929887 | Seoul National University Hospital | — |
| Completed | LDL-Apheresis for FSGS CardioRenal Outcomes NCT04088799 | Children's Hospital Medical Center, Cincinnati | — |
| Completed | Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesa NCT03649152 | Dimerix Bioscience Pty Ltd | Phase 2 |
| Terminated | A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome NCT03703908 | Amgen | Phase 2 |
| Unknown | Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome NCT03298698 | Radboud University Medical Center | Phase 3 |
| Terminated | Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulos NCT03598036 | Aurinia Pharmaceuticals Inc. | Phase 2 |
| Completed | A Study of CCX140-B in Subjects With FSGS NCT03536754 | Amgen | Phase 2 |
| Completed | Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) NCT03493685 | Travere Therapeutics, Inc. | Phase 3 |
| Completed | A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases NCT03366337 | Biogen | Phase 2 |
| Completed | Predictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis NCT03126201 | Istanbul University | — |
| Unknown | Valproic Acid for Idiopathic Nephrotic Syndrome NCT02896270 | Universitair Ziekenhuis Brussel | Phase 2 / Phase 3 |
| Completed | Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Exc NCT02592798 | Bristol-Myers Squibb | Phase 2 |
| Completed | Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial NCT02585804 | University Health Network, Toronto | Phase 4 |
| Completed | Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis NCT02693366 | Universidade Federal do Rio de Janeiro | Phase 1 |
| Recruiting | Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Chil NCT02235857 | Kaneka Medical America LLC | N/A |
| Unknown | Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis) NCT02382874 | Royan Institute | Phase 1 |
| Completed | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomeruloscleros NCT01613118 | Travere Therapeutics, Inc. | Phase 2 |
| Completed | Regional Citrate Anticoagulation in Plasma Exchange Treatment NCT01370200 | University Medical Centre Ljubljana | N/A |
| Recruiting | National Registry of Rare Kidney Diseases NCT06065852 | UK Kidney Association | — |
| Completed | Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome NCT01113385 | Children's National Research Institute | N/A |
| Terminated | Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney NCT01129557 | Columbia University | Phase 4 |
| Unknown | Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis NCT00956059 | Xi'an Jiaotong University | N/A |
| Completed | Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosc NCT00801463 | Nanjing University School of Medicine | N/A |
| Terminated | Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor NCT00816478 | Northwell Health | Phase 1 |
| Withdrawn | Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5 NCT00816504 | Northwell Health | Phase 1 |
| Completed | Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial NCT00814255 | NYU Langone Health | Phase 2 |
| Terminated | Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis NCT00883636 | Northwell Health | — |
| Terminated | Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS NCT00782561 | Kyntra Bio | Phase 1 |
| Completed | Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in NCT00464321 | Genzyme, a Sanofi Company | Phase 1 |
| Completed | Kidney Disease Biomarkers NCT00255398 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | — |
| Completed | Permeability Factor in Focal Segmental Glomerulosclerosis NCT00007475 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 1 / Phase 2 |
| Active Not Recruiting | Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure NCT02194582 | Beth Israel Deaconess Medical Center | — |
| Completed | Genetic Markers for Focal Segmental Glomerulosclerosis NCT00001393 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | — |